Apixaban

CAS 503612-47-3 53 current records 4 historicalSmall Molecule

Who holds supplier records for Apixaban? 53 organisations hold a current record for Apixaban: an active US FDA Type II Drug Master File. A further 4 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (36), China (8), Canada (1), Malta (1) and 4 other countries (4); not recorded for 3.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Apixaban: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/apixaban

Reading the evidence

  • 53 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    36 of the 50 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 27 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Apixaban expires 22 May 2041. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (53)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Apixaban. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Apixaban sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (4)

Organisations whose Type II DMFs for Apixaban are no longer active. These show a past filing, not current supply.

Show all 4 historical records

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (8 listed products contain Apixaban). The latest listed patent expires 22 May 2041. The latest listed exclusivity runs to 17 Oct 2028. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Apixaban is an oral anticoagulant medication that works by inhibiting factor Xa, an important component in the blood coagulation pathway. It is commonly used to prevent and treat blood clots and reduce the risk of stroke in patients with atrial fibrillation.

Chemical identity

IUPAC name
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[5,4-c]pyridine-3-carboxamide
Canonical SMILES
COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N
InChIKey
QNZCBYKSOIHPEH-UHFFFAOYSA-N
Synonyms
Apixaban, Eliquis, bms-562247, bms-562247-01

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Factor Xa Inhibitor
Mechanism of action
Factor Xa Inhibitors

Therapeutic areas

CardiovascularHematology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Apixaban?

53 organisations hold an active US FDA Type II Drug Master File or a CEP for Apixaban: MOREPEN LABORATORIES LTD (India), MSN Laboratories Private Limited (India), Neuland Laboratories Limited (India), AARTI PHARMALABS LIMITED (India), Alembic Pharmaceuticals Limited (India), ALIVUS LIFE SCIENCES LTD (India), ALP PHARM BEIJING CO LTD and AMOLI ORGANICS (A DIVISION OF UMEDICA LABORATORIES PVT LTD) (India), and 45 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Apixaban Drug Master Files are active?

MOREPEN LABORATORIES LTD (DMF 35799, 36641), MSN Laboratories Private Limited (DMF 31089, 28009), Neuland Laboratories Limited (DMF 39444, 32422), AARTI PHARMALABS LIMITED (DMF 35969), Alembic Pharmaceuticals Limited (DMF 29660), ALIVUS LIFE SCIENCES LTD (DMF 30060), ALP PHARM BEIJING CO LTD (DMF 34954) and AMOLI ORGANICS (A DIVISION OF UMEDICA LABORATORIES PVT LTD) (DMF 38900) and 45 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Apixaban records mean?

4 organisations have only inactive Type II DMFs for Apixaban. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does the FDA Orange Book list patents for products containing Apixaban?

Yes. The latest patent listed for an approved US product containing Apixaban expires 22 May 2041, across 8 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Apixaban supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Apixaban?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.